NanoString posts higher revenues, lower net loss in Q1
Strong growth in product and service revenues helped NanoString Technologies reach 18.8% total revenue growth and a lower net loss in its first quarter. Read More
Lilly, MiNA collaborate on saRNA research
Eli Lilly is teaming up with RNA activation therapeutics firm MiNA Therapeutics on a global research collaboration to develop drug candidates using MiNA's small activating RNA (saRNA) technology platform. Read More
Akoya Biosciences seeks Imaging Innovators Network researchers
Akoya Biosciences is looking for researchers to join its new Imaging Innovators (I2) Network, a collaborative initiative that aims to support open innovation in spatial biology. Read More
Appia Bio launches to develop stem cell-based cell therapies
Appia Bio has launched from stealth as an early-stage biotechnology company focused on the development of engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients. The company will be initially backed by $52 million in financing. Read More
Adaptive Phage Therapeutics gets $40.8M to advance its phage therapies
Adaptive Phage Therapeutics has closed $40.8 million in financing to accelerate the clinical development of its PhageBank phage therapies. Read More
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents ages 12 to 15 years. Read More
Novavax posts positive preclinical results for flu/COVID-19 vaccine
Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine. Read More
Inovio touts COVID-19 phase II vaccine results
Inovio is highlighting results from its phase II clinical trial evaluating its COVID-19 DNA vaccine. Read More
Altimmune's intranasal COVID-19 vaccine shows sterilizing potential
Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose. Read More
SARS-CoV-2 vaccine candidate shows promise against variants
A pancoronavirus vaccine candidate created by the Infectious Disease Research Institute, the Duke Human Vaccine Institute, and 3M shows potential to protect against variants of SARS-CoV-2, according to a study published May 10 in Nature. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
